Screener
R&D at other companies
Other financials
Where this comes from
Reported directly by Ionis Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The source filing: Ionis Pharmaceuticals’s 10-K, filed February 26, 2026.
- Filed
- Feb 26, 2026, 4:25 PM EST
- Fiscal year
- FY2026
- Accession
- 0000874015-26-000115
| Line item | Year Ended December 31, 2025 | Year Ended December 31, 2024 | Year Ended December 31, 2023 |
|---|---|---|---|
| Total revenue | 943,711 | 705,138 | 787,647 |
| Expenses: | |||
| Cost of sales | 15,909 | 11,215 | 9,133 |
| Research, development and patent | 915,619 | 901,530 | 899,625 |
| Selling, general and administrative | 393,867 | 267,474 | 232,619 |
| Total operating expenses | 1,325,395 | 1,180,219 | 1,141,377 |
| Loss from operations | (381,684) | (475,081) | (353,730) |
| Other income (expense): |
Item 15. Exhibits and Financial Statement Schedules
FAQ
- What is Ionis Pharmaceuticals's R&D?
- Ionis Pharmaceuticals (IONS) reported R&D of $228.9M in Q4 2025.
- How has Ionis Pharmaceuticals's R&D changed year-over-year?
- Ionis Pharmaceuticals's R&D increased by 1.6% year-over-year, from $225.38M to $228.9M.
- What is the long-term trend for Ionis Pharmaceuticals's R&D?
- Over 2 years (2023 to 2025), Ionis Pharmaceuticals's R&D has grown at a 0.9% compound annual growth rate (CAGR), from $899.63M to $915.62M.
- What does R&D mean?
- Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.
Ask your AI about Ionis Pharmaceuticals's r&d.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude